NYSE$SOLV

Solventum Corporation · Q1 2023 earnings

Q1 2023 earnings · · Investor relations

Headline financials

Total Revenue

$2.01B

Previous: $2.06B-2.3%
EPS (adj)

$1.70

Previous: $2.03-16.3%
Capital Expenditures

$65M

No prior period
Free Cash Flow

$444M

No prior period
Net Income

$293M

Previous: $351M-16.4%
Operating Income

$411M

Previous: $443M-7.2%
Gross Profit

$1.16B

Previous: $1.22B-4.6%
Cash & Equivalents

$43M

No prior period
Stock-Based Comp

$18M

No prior period

Revenue & EPS history

Solventum · Revenue · Quarterly

$2.01B

Q1 2023-2.3%vs Q1 2022
Beat estimate in 6 of 10 quarters(60%)
ActualEstimate

Revenue by segment

Solventum · $1.78B total across 3 segments · Q1 2023

  • MedSurg
    $1.12B
  • Dental Solutions
    $341M
  • Health Information Systems
    $316M

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 12 quarterly earnings reports · overlaid with Q1 2023

Historical avgQ1 2023

+0.2%

Avg return

Earnings day

+0.1%

Avg return

5 days after

+2.1%

Avg return

30 days after

42%

5 / 12 earnings

Positive

+8.4%

Q2 2024

Best reaction

-4.7%

Q3 2023

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026+2.4%+8.7%+21.2%
Q4 2025-3.7%-8.5%-18.4%
Q3 2025+7.7%+11.4%+28.9%
Q2 2025+1.7%+3.4%+1.1%
Q1 2025+5.5%+6.8%+12.3%
Q4 2024-4.4%-6.7%-10.4%
Q3 2023-4.7%-6.7%-6.8%
Q3 2024-2.3%-4.6%-5.6%
Q2 2023-1.6%-1.5%+12.9%
Q2 2024+8.4%+4.2%+18.4%
Q1 2023-2.6%-3.7%-13.0%
Q1 2024-4.0%-2.0%-15.1%
Q4 2023
Q4 2022
Q3 2022
Q2 2022
Q1 2022

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro